An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A recent piece in MIT Technology Review raises concern that a class of weight-loss drugs known as GLP-1s might be linked to an increase in eating disorders. The report notes that both rates of eating disorders and the use of GLP-1 drugs (like Ozempic and Wegovy) have gone up, and it explores whether the drugs could be contributing to new or worsening cases. The article doesn't claim a proven cause-and-effect link yet, but it highlights growing worry among doctors, patients, and researchers. GLP-1s are drugs that copy a natural hormone called glucagon-like peptide-1. That hormone is released by your gut after you eat and tells your brain to feel full, slows how quickly your stomach empties, and helps control blood sugar. In drug form, GLP-1s make people eat less and lose weight, which is why they are prescribed for obesity and type 2 diabetes. Lots of people know them by brand names, but the important idea is that these drugs change appetite and the physical sensation of hunger. What the report actually shows is mostly observational and anecdotal evidence, plus some early clinical signals. Doctors and therapists are seeing more patients who report disordered eating behaviors—bingeing, extreme restriction, obsessive calorie counting—after starting GLP-1s, or who struggle when they stop the drugs. Some small studies and surveys suggest an association, but there aren’t large, long-term clinical trials conclusively proving GLP-1s cause eating disorders. The increase could also reflect more awareness, more people seeking treatment, or societal pressures around weight. In short: there are worrying signs, but not yet definitive proof. This matters because GLP-1s are being used by millions and often promoted for weight loss. If the drugs increase the risk of developing disordered eating or make existing eating disorders worse, that changes how doctors should screen and monitor patients. People with a history of anorexia, bulimia, binge-eating, or body image issues might need extra counseling before starting these medications. It also matters for parents and young adults, since eating disorders often begin in adolescence and early adulthood. There are important caveats. Side effects like nausea, constipation, or reduced appetite are common and expected; those are not the same as an eating disorder. Eating disorders are psychological conditions with behavioral and emotional patterns, and it’s hard to untangle whether a drug’s appetite-suppressing effect triggers those patterns or simply unmasks a preexisting vulnerability. Regulators have not withdrawn these drugs; they remain approved for certain uses. But clinicians warn of unknowns: long-term mental-health effects, how stopping the drugs affects eating behavior, and who is most at risk. People with known eating disorders or severe body-image concerns should discuss risks with their doctor or a mental-health professional before using GLP-1s. Bottom line: GLP-1 drugs are effective at reducing appetite and weight for many, but there are real, if not yet proven, concerns that they could contribute to or worsen eating-disorder symptoms in some people. If you’re considering one of these medications, ask about mental-health screening and ongoing monitoring.
Source: MIT Technology Review